Fellows' Journal Club

2016-2017 Academic Year

Date Speaker Title Link
Jul 26, 2016
Ted Thomas Non-small-cell lung cancer
Gefitinib Plus Chemotherapy Versus Placebo Plus Chemotherapy in EGFR-Mutation-Positive Non-Small-Cell Lung Cancer After Progression on First-Line Gefitinib (IMPRESS): A Phase 3 Randomised Trial
  Sid Devarakonda Afatinib Versus Gefitinib as First-Line Treatment of Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer (LUX-Lung 7): A Phase 2B, Open-Label, Randomised Controlled Trial PubMed
  Jeff Ward
Faculty Discussant
Aug 24, 2016 Bita Fakhri Acute myeloid leukemia
Genomic Classification and Prognosis in Acute Myeloid Leukemia
  Francesca Ferraro Pre- and Post-Transplant Quantification of Measurable ('Minimal') Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia PubMed
  Geoff Uy
Faculty Discussant
Sep 28, 2016 Andy Liao Breast cancer
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials
  Lingling Du Adjuvant Ovarian Suppression in Premenopausal Breast Cancer PubMed
  Kathy Weilbaecher
Faculty Discussant
Oct 26, 2016 Patrick Grierson Lower GI
Circulating Tumor DNA Analysis Detects Minimal Residual Disease and Predicts Recurrence in Patients With Stage II Colon Cancer
  Stephen Barman PD-1 Blockade in Tumors with Mismatch-Repair Deficiency PubMed
  Kian-Huat Lim
Faculty Discussant
Nov 23, 2016 Nusayba Bagegni Upper GI
Histopathological Regression After Neoadjuvant Docetaxel, Oxaliplatin, Fluorouracil, and Leucovorin Versus Epirubicin, Cisplatin, and Fluorouracil or Capecitabine in Patients With Resectable Gastric or Gastro-Oesophageal Junction Adenocarcinoma (FLOT4-AIO): Results From the Phase 2 Part of a Multicentre, Open-Label, Randomised Phase 2/3 Trial
  Eric Huselton Ramucirumab Plus Paclitaxel Versus Placebo Plus Paclitaxel in Patients With Previously Treated Advanced Gastric or Gastro-Oesophageal Junction Adenocarcinoma (RAINBOW): A Double-Blind, Randomised Phase 3 Trial PubMed
  Benjamin Tan
Faculty Discussant
Dec 15, 2016
Sana Saif Ur Rehman Myeloproliferative neoplasms
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
  Natasha Edwin Cardiovascular events and intensity of treatment in polycythemia vera
  Steve Oh
Faculty Discussant
Jan 25, 2017 Eric Huselton Chronic lymphocytic leukemia
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
  Bita Fakhri Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia PubMed
  Camille Abboud
Faculty Discussant
Feb 22, 2017 Natasha Edwin Thrombosis/Anticoagulation
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A
  Aabha Oza Recurrent Venous Thromboembolism and Abnormal Uterine Bleeding With Anticoagulant and Hormone Therapy Use PubMed
  Amy Zhou
Faculty Discussant
Mar 22, 2017 Stephen Barman Genitourinary
Cabozantinib Versus Everolimus in Advanced Renal Cell Carcinoma (METEOR): Final Results From a Randomised, Open-Label, Phase 3 Trial
  Systemic Therapy for Metastatic Renal-Cell Carcinoma PubMed
  Tom Regenbogen Quality of Life in Long-Term Survivors of Muscle-Invasive Bladder Cancer PubMed
  Long-Term Outcomes After Bladder-Preserving Tri-Modality Therapy for Patients With Muscle-Invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience PubMed
  James Hsieh
Faculty discussant
  Joel Picus
Faculty Discussant
Apr 26, 2017 Amber Xu Melanoma
Combination of Dabrafenib Plus Trametinib for BRAF and MEK Inhibitor Pretreated Patients With Advanced BRAFV600-Mutant Melanoma: An Open-Label, Single Arm, Dual-Centre, Phase 2 Clinical Trial
  Nkiruka Ezenwajiaku Combined Nivolumab and Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Melanoma: 2-Year Overall Survival Outcomes in a Multicentre, Randomised, Controlled, Phase 2 Trial PubMed
  Jesse Keller
Faculty Discussant
May 31, 2017 Tanner Johanns Primary Gliomas
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
  Pavan Bhamidipati Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma PubMed
  Jian Campian
Faculty Discussant
Jun 21, 2017 Pavan Bhamidipati Brain Metastases
Alectinib Versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer
  Amber Afzal Management of Brain Metastases in Tyrosine Kinase Inhibitor-Na├»ve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis PubMed
  Saiama Waqar
Faculty Discussant